Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.

Togasaki E, Takeda J, Yoshida K, Shiozawa Y, Takeuchi M, Oshima M, Saraya A, Iwama A, Yokote K, Sakaida E, Hirase C, Takeshita A, Imai K, Okumura H, Morishita Y, Usui N, Takahashi N, Fujisawa S, Shiraishi Y, Chiba K, Tanaka H, Kiyoi H, Ohnishi K, Ohtake S, Asou N, Kobayashi Y, Miyazaki Y, Miyano S, Ogawa S, Matsumura I, Nakaseko C, Naoe T.

Blood Cancer J. 2017 Apr 28;7(4):e559. doi: 10.1038/bcj.2017.36.

2.

Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.

Kim T, Tyndel MS, Zhang Z, Ahn J, Choi S, Szardenings M, Lipton JH, Kim HJ, Kim Dong Hwan D.

Leuk Res. 2017 Aug;59:142-148. doi: 10.1016/j.leukres.2017.06.009. Epub 2017 Jun 16.

PMID:
28667884
3.

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.

Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R.

Leuk Res. 2014 Apr;38(4):454-9. doi: 10.1016/j.leukres.2013.12.025. Epub 2014 Jan 6.

PMID:
24456693
4.

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.

Ben-Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus JL, Rankin S, Clark RE, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf TH, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason GV, Holyoake TL, Loges S.

Clin Cancer Res. 2017 May 1;23(9):2289-2300. doi: 10.1158/1078-0432.CCR-16-1930. Epub 2016 Nov 17.

5.

Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.

Soverini S, de Benedittis C, Mancini M, Martinelli G.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S120-8. doi: 10.1016/j.clml.2015.02.035. Review.

PMID:
26297264
6.

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.

Schmidt M, Rinke J, Schäfer V, Schnittger S, Kohlmann A, Obstfelder E, Kunert C, Ziermann J, Winkelmann N, Eigendorff E, Haferlach T, Haferlach C, Hochhaus A, Ernst T.

Leukemia. 2014 Dec;28(12):2292-9. doi: 10.1038/leu.2014.272. Epub 2014 Sep 12.

PMID:
25212276
7.

Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.

Moore FR, Yang F, Press RD.

Methods Mol Biol. 2013;999:25-39. doi: 10.1007/978-1-62703-357-2_2.

PMID:
23666688
8.

CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.

Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, Dujardin S, Cazzolli H, Przychodzen B, Prince C, Nicoll J, Siddaiah H, Shaik M, Szpurka H, Hsi E, Advani A, Paquette R, Maciejewski JP.

Blood. 2011 May 26;117(21):e198-206. doi: 10.1182/blood-2010-06-292433. Epub 2011 Feb 23.

9.

BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.

Wongboonma W, Thongnoppakhun W, Auewarakul CU.

Exp Mol Pathol. 2012 Apr;92(2):259-65. doi: 10.1016/j.yexmp.2012.01.007. Epub 2012 Jan 31.

PMID:
22314255
10.

Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.

Marcé S, Zamora L, Cabezón M, Xicoy B, Boqué C, Fernández C, Grau J, Navarro JT, Fernández de Sevilla A, Ribera JM, Feliu E, Millá F; Grupo ICO de estudio de mutaciones de ABL en pacientes afectos de LMC.

Med Clin (Barc). 2013 Aug 4;141(3):95-9. doi: 10.1016/j.medcli.2012.10.028. Epub 2013 Feb 22.

PMID:
23433665
11.

Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.

Ferri C, Bianchini M, Bengió R, Larripa I.

Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):121-5. doi: 10.1016/j.bcmd.2013.09.002. Epub 2013 Oct 3.

PMID:
24091144
12.

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.

Korfi K, Mandal A, Furney SJ, Wiseman D, Somervaille TC, Marais R.

Ann Oncol. 2015 Jun;26(6):1180-7. doi: 10.1093/annonc/mdv110. Epub 2015 Feb 23.

13.

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.

Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J.

Blood. 2009 Sep 3;114(10):2037-43. doi: 10.1182/blood-2009-01-197715. Epub 2009 Jun 30.

14.

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.

Soverini S, De Benedittis C, Castagnetti F, Gugliotta G, Mancini M, Bavaro L, Machova Polakova K, Linhartova J, Iurlo A, Russo D, Pane F, Saglio G, Rosti G, Cavo M, Baccarani M, Martinelli G.

BMC Cancer. 2016 Aug 2;16:572. doi: 10.1186/s12885-016-2635-0.

15.

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.

Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, Müller MC, Radich JP, Shah NP.

Leuk Res. 2014 Jan;38(1):10-20. doi: 10.1016/j.leukres.2013.09.011. Epub 2013 Sep 23. Review.

16.

Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.

Egan DN, Beppu L, Radich JP.

Biol Blood Marrow Transplant. 2015 Jan;21(1):184-9. doi: 10.1016/j.bbmt.2014.09.012. Epub 2014 Oct 6.

17.

ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.

Wang Z, Liu Z, Wu X, Chu S, Wang J, Yuan H, Roth M, Yuan YC, Bhatia R, Chen W.

PLoS Genet. 2014 Jun 26;10(6):e1004414. doi: 10.1371/journal.pgen.1004414. eCollection 2014 Jun. Erratum in: PLoS Genet. 2015 Mar;11(3):e1005033.

18.

BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.

McCarron SL, O'Connor LM, Langabeer SE, Conneally E.

Genet Test Mol Biomarkers. 2013 Feb;17(2):170-3. doi: 10.1089/gtmb.2012.0272. Epub 2013 Jan 5.

PMID:
23289634
19.

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.

Bandyopadhyay S, Li J, Traer E, Tyner JW, Zhou A, Oh ST, Cheng JX.

PLoS One. 2017 Jul 18;12(7):e0179558. doi: 10.1371/journal.pone.0179558. eCollection 2017.

20.

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.

Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S, Porkka K.

Oncotarget. 2017 Apr 4;8(14):22606-22615. doi: 10.18632/oncotarget.15146.

Supplemental Content

Support Center